Iridex to Host Strategic Vision Call on April 16, 2025
Rhea-AI Summary
Iridex (Nasdaq: IRIX), a leading provider of laser-based medical systems for glaucoma and retinal diseases, has announced a strategic vision call scheduled for April 16, 2025. The call will outline the company's strategic direction following Novel's recent strategic investment.
The conference call is set to begin at 2:00 p.m. PT / 5:00 p.m. ET. Investors can participate by dialing 888-596-4144 with conference ID: 9584140. Both a live and recorded webcast will be accessible through the 'Event Calendar' section on Iridex's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, IRIX gained 0.82%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel’s strategic vision for the Company following Novel’s recent strategic investment in Iridex.
The Company’s management team will host a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 888-596-4144 and providing conference ID: 9584140. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When is Iridex (IRIX) hosting its strategic vision call in 2025?
How can investors join Iridex's (IRIX) April 2025 strategic vision call?
What will be discussed in Iridex's (IRIX) upcoming strategic vision call?
Where can investors find the recorded webcast of Iridex's (IRIX) strategic vision call?
